The European Union has approved GSK's acquisition of Pfizer's consumer health business

The European Commission recently announced that it has approved GlaxoSmithKline's (GSK) acquisition of Pfizer's consumer health business under EU merger regulations, a decision that will depend on Pfizer's global divestiture of local pain management products under the ThermaCare brand.According to the survey, the European Commission is concerned that both companies are suppliers of local pain management products, and that acquisitions will reduce competition between such products, leading to higher prices in some EEA countries, including Austria, Germany, Ireland, Italy and the Netherlands.To resolve the issue, the EU proposed that Pfizer spin off the business globally, and that the assets be approved by the European Commission and sold as a whole to a suitable buyer.On December 19th Pfizer and GlaxoSmithKline announced separately that they had reached an agreement to merge their consumer health businesses, with the new company operating globally under the name GlaxoSmithKline Consumer Health, which will be merged with GlaxoSmithKline Consumer Health Products.On the 11th of last month, GSK Consumer Health Products and Pfizer Health Pharmaceuticals announced the new company's organizational structure, in which the Asia Pacific region is still under the responsibility of former Pfizer Asia Pacific President Cai Baoguang, former Pfizer Health Pharmaceuticals China General Manager Gu Haiying was appointed the new company's General Manager for Greater China. (Medical representative)